Allostery Investments LP increased its position in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 44.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,329,384 shares of the company's stock after buying an additional 714,258 shares during the period. Zura Bio comprises 4.3% of Allostery Investments LP's portfolio, making the stock its 9th largest holding. Allostery Investments LP owned approximately 3.41% of Zura Bio worth $3,005,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of ZURA. Two Sigma Advisers LP bought a new stake in Zura Bio in the 4th quarter valued at about $32,000. ProShare Advisors LLC purchased a new position in Zura Bio during the fourth quarter valued at approximately $35,000. Wells Fargo & Company MN grew its position in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock worth $58,000 after acquiring an additional 9,379 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Zura Bio in the fourth quarter worth $62,000. Finally, Dimensional Fund Advisors LP acquired a new position in Zura Bio during the 4th quarter valued at $93,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.
Zura Bio Stock Down 1.1%
NASDAQ:ZURA traded down $0.02 on Monday, hitting $2.18. The stock had a trading volume of 201,728 shares, compared to its average volume of 501,186. Zura Bio Limited has a 52-week low of $0.97 and a 52-week high of $5.07. The stock has a market cap of $141.48 million, a price-to-earnings ratio of -3.12 and a beta of -0.02. The business's 50-day simple moving average is $1.61 and its two-hundred day simple moving average is $1.36.
Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Oppenheimer dropped their target price on shares of Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, August 15th. HC Wainwright dropped their price target on shares of Zura Bio from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 19th. Finally, Chardan Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $14.00.
Get Our Latest Report on Zura Bio
Zura Bio Company Profile
(
Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Read More

Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.